Dr. James S. Lewis II, Antibiotic Susceptibility Test Expert, Joins as Chair of Selux Diagnostics’ Clinical Advisory BoardOctober 18, 2022
Selux Diagnostics Awarded $2.8 Million Grant from NIH for Commercialization of its NGP PlatformOctober 19, 2021
Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation ‘Phenotyping’ (NGP) Platform for Positive Blood Culture and Sterile Body Fluid SamplesSeptember 28, 2021
Selux Diagnostics Receives Additional $14.6 Million in BARDA Funding After Successfully Completing First Clinical TrialJune 9, 2021
Selux Diagnostics Receives $9.6 Million in Additional Funding, Speeding Development of Breakthrough Rapid AST PlatformApril 27, 2020
ECCMID 2020 Alert: Selux Diagnostics Hosting Integrated Symposium at 30th European Congress of Clinical Microbiology & Infectious DiseasesFebruary 18, 2020
Selux Diagnostics Announces Selection of Three Abstracts for Poster Sessions at ASM Microbe ConferenceJune 10, 2019